Thousand Oaks-based biotech giant Amgen said this morning that it has agreed to buy KAI Pharmaceuticals, a developer of treatments for secondary hyperparathyroidism (SHPT) in patients with chronic kidney disease (CKD) who are on dialysis, for $315M in cash. KAI Pharmaceuticals is based in South San Francisco. Amgen said it gains worldwide rights to KAI's lead compound, excluding Japan. KAI Pharmaceuticals will become a wholly owned subsidiary of Amgen. KAI was venture backed by InterWest Partners, Skyline Ventures, Intersouth Partners, Aberdare Ventures, Investor Growth Capital, Kearny Venture Partners, Lumira Capital and Delphi Ventures.
Top NewsTuesday, April 10, 2012
Amgen Buys KAI Pharmaceuticals